Demographics, Subgroup Analyses, and Statistical Considerations in Cluster Randomized Trials
|
|
- Deborah Walsh
- 5 years ago
- Views:
Transcription
1 Demographics, Subgroup Analyses, and Statistical Considerations in Cluster Randomized Trials Monique L. Anderson, MD MHS Assistant Professor of Medicine Division of Cardiology Duke Clinical Research Institute Duke University School of Medicine
2 Aims Definition of Terms to Describe HTE Review of Federal Policies for HTE analyses Systematic Review on Demographic Reporting and Subgroup Analyses Simulation Models to explore impact of imbalance of demographic subgroups
3 Definitions Cluster Randomized Trial 1,2 Experiments in which intact social units, rather than independent individuals, are randomly assigned to intervention groups CRT designs may be chosen to avoid contamination, randomization of individuals is not possible, to evaluate interventions that operate at a group level or manipulate the social or physical environment. Treatment Effect 3 - A comparison between treatment groups in a trial. Usually measured by relative risk, odds ratio, or arithmetic difference Subgroup Analysis 3- Any evaluation of treatment effects for a specific endpoint in subgroups of patients defined by baseline characteristics Undertaken to investigate consistency of trial conclusions across different subpopulations who are defined by multiple baseline characteristics. Also called heterogeneity of treatment effect analysis Heterogeneity of Treatment Effect 3 - Refers to circumstances in which the treatment effects vary across levels of baseline characteristics E.g. Men versus Women, Black race versus White Race Expressed in a statistical model as an interaction term between treatment group and baseline variable. 1. Donner, A. Appl. Statistics (1998) 47, Murray, D et al. J Natl Cancer Ist 2008:100: Wang, R wt al. NEJM 2007; 357:
4 FDA Policies and Guidance for Race and Ethnicity Reporting and HTE Analyses Guidelines for the Format and Content of Clinical and Statistical Sections of NDAs Emphasized the importance of subgroup analyses, specified race and ethnicity subgroups should be analyzed Demographic Rule- ½ NDAs have sufficient analyses Sponsors of IND applications to submit annual demographics of enrolled population NDA required to submit effectiveness and safety data for demographic subgroups FDA Guidance on Reporting Race and Ethnicity Reporting in Clinical Research OMB Categories Recommended FDAAA 801- Reporting of Basic Results Mandatory for Applicable Clinical Trial Race and Ethnicity Reporting is Optional ; Age and Sex Mandatory Final rule for FDAAA now mandates reporting of race and ethnicity to CT.gov Section 907 FDASIA Action Plan to improve demographic reporting and HTE 2016 Race and ethnicity now required in submission of results to clinicaltrials.gov NIH now requires all funded clinical trials to report data to website.
5 NIH Policies on Minority Inclusion and HTE 1993 NIH Revitalization Act Directs the NIH to establish guidelines for inclusion of women and minorities in clinical research Established Office of Minority Health and Office of Women s Health 1994 NIH Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research Inclusion of minorities to be addressed in funding proposals and annual progress reports Phase III trials must examine HTE where applicable OMB standards revised Guidelines Updated Research Plan, Progress Reports, Competitive Renewal Apps, Final Progress Reports to include plan for subgroup analyses Subgroup analyses strongly encouraged in all publication submissions NIH Policy on Reporting Race and Ethnicity Data: Subjects in Clinical Research OMB revised standards adopted by the NIH Inclusions Guidelines Updated to reflect OMB categories
6 NIH Inclusion Policy: Additional Guidance on HTE for Clinical Trials Prior Data HTE Analysis Required Sufficient Power Needed to Detect Difference in Subgroups Support HTE by race/ethnicity Mandatory Yes Neither support or negate HTE Yes No Does not support HTE Encouraged No
7 Heterogeneity of Treatment Effect in CRTs for Baseline Demographics Pragmatic clinical trials may be optimal for understanding how standard treatments impact demographic subgroups. It is unclear how to address demographic subgroups in CRTs (if they should be addressed at all). Cluster randomization Currently, no federal policies or guidance exist for addressing demographic inclusion and analysis in CRTs. design and analysis
8 Research Aims 1. Systematic Review: Cluster Randomized Trials 1. Define proportion of CRTs that report on demographics. 2. Report on the frequency of addressing demographic subgroups in design or analysis of CRTs in literature. 3. Describe the degree to which heterogeneity of treatment effect analyses are conducted overall and for demographic subgroups. 2. Simulation Modeling: 1. Describe preliminary results of simulation computer models to quantify the impact of racial imbalance on treatment effect bias. 2. Understand whether any detected bias due to imbalance is overcome by commonly used statistical approaches in CRTs.
9 Systematic Review PubMed and EMBASE database search: CRTs published between Jan 2010 and March Key Questions How often and with what methods are heterogeneity of treatment effects (HTE) explored in published CRTs targeting the top 3 leading causes of death? How often are HTE analyses conducted for demographic subgroups in published CRTs targeting the top 3 leading causes of death? How do these findings differ given clinical area, intervention type, and key characteristics of the population studied? Definitions Center for Disease Control Definition of Leading Causes of Death Heart Disease, Chronic Lower Respiratory Diseases, and Cancer ICD 9/10 codes used to identify diseases in each clinical area Prevention trials only included if patients had the diseases of interest (ex. study aimed to prevent coronary artery disease, but not a study that prevented diabetes or hypertension).
10 Literature Flow Diagram 1939 citations identified by literature search: PubMed: 1422 Embase: duplicates 1682 unique citations identified 117 passed abstract screening 65 articles (65 studies) passed full-text screening and were abstracted 65 abstracted studies: Cardiovascular Disease: 18 studies Chronic Lower Respiratory Disease: 31 studies Cancer: 16 studies 1565 abstracts excluded 52 articles excluded: - Not a publication type of interest (study protocol, editorial, systematic/ nonsystematic review, meta-analysis, letter): 11 - Not a cluster-randomized trial: 3 - Study population is not individuals with a disease of interest: 24 - Does not report any patient-level outcomes: 5 - Not the primary/main report of the study results: 9
11 CRT Systematic Review: Study Characteristics Study Characteristics of CRTs All Cancer Cardiovascular Pulmonary N= 65 N= 16 N= 18 N= 31 Geographic Location, n (%) US 13 (20%) 2 (12.5%) 4 (22.2%) 7 (22.6%) Non-US 49 (75.4%) 14 (87.5%) 11 (61.1%) 24 (77.4%) Mixed 3 (4.6%) 0 (0%) 3 (16.7%) 0 (0%) Funding Source, n(%) Government 20 (30.8%) 5 (31.25%) 5 (27.8%) 10 (32.3%) Industry 2 (3.1%) 0 (0%) 1 (5.5%) 1 (3.2%) Non-Gov, Non-Industry 6 (9.2%) 1 (6.25%) 2 (11.1%) 3 (9.7%) Mixed sources 22 (33.8%) 6 (37.5%) 5 (27.8%) 11 (35.5%) Unclear 15 (23.1%) 4 (25%) 5 (27.8%) 6 (19.4%) Setting, n (%) Clinic 41 (63.1%) 10 (62.5%) 6 (33.3%) 25 (80.6%) Hospital 13 (20%) 6 (37.5%) 6 (33.3%) 1 (3.2%) Emergency Medical Services 6 (9.2%) 0 (0%) 4 (22.2%) 2 (6.5%) School/Community 2 (3.1%) 0 (0%) 1 (5.6%) 1 (3.2%) Other 3 (4.6%) 0 (0%) 1 (5.6%) 2 (6.5%) Intervention, n (%) Devices 3 (4.6%) 0 (0%) 2 (11.1%) 1 (3.2%) Drug or Biologic 0 (0%) 0 (0%) 0 (0%) 0 (0%) Quality Improvement 33 (50.8%) 11 (68.75%) 9 (50%) 13 (41.9%) Behavioral Interventions 12 (18.5%) 2 (12.5%) 4 (22.2%) 6 (19.4%) Mixed Interventions 7 (10.8%) 2 (12.5%) 0 (0%) 5 (16.1%) Other 10 (15.4%) 1 (6.25%) 3 (16.7%) 6 (19.4%) Number of Patients Enrolled, median (IQR) (263, 1108) (243.5, 505.5) 1405 (637, ) 427 (307, 878) Number of Clusters Enrolled, median (IQR) 40 (18.5, 95) 17 (12, 87.8) 98 (39, 174) 39 (23, 49)
12 Reporting of Baseline Characteristics in CRTs Baseline Characteristics All Cancer Cardiovascular Pulmonary N= 65 N=16 N=18 N=31 Baseline Characteristics Reported, % 62 (95.4%) 16 (100%) 18 (100%) 28 (90.3%) Age, % reported 56 (86.1%) 14 (87.5%) 18 (100%) 24 (77.4%) Sex, % reported 58 (89.2%) 15 (93.8%) 18 (100%) 25 (80.6%) Race and/or Ethnicity, % reported 12 (18.4%) 3 (18.8%) 4 (22.2%) 5 (16.1%) All NIH Categories White Race Only Category, other than white race > 1 Race Category Socioeconomic Status, % reported 25 (38.5%) 9 (56.3%) 5 (27.8%) 11 (35.5%) Income Level Level of Education Social Class Insurance Status Other
13 Primary Outcomes in CRTs Primary Outcomes All Cancer Cardiovascular Pulmonary N =65 N = 16 N = 18 N = 31 Primary Outcome Identified 60 (92.3%) 15 (93.8%) 18 (100%) 27 (87.1%) Type of Outcome Patient Reported Outcome 27 (45.0%) 10 (66.7%) 2 (11.1%) 15(55.6%) Clinical Outcome 15 (25.0%) 3 (20.0%) 5 (27.8%) 7 (25.9%) Mortality/Survival 8 (30.0%) 0 7 (38.9%) 1 (3.7%) Process Outcome 9 (15.0%) 2 (13.3%) 5 (27.8%) 2(6.5%) Economic Outcome 1 (1.7%) (3.7%) Behavioral Outcome 1 (1.7%) (3.7%) Power Analysis Reported 50 (76.9%) 10 (62.5%) 16 (88.9%) 24 (77.4%) ICC presented 35 (53.8%) 7 (43.8%) 10 (55.5%) 18 (58.1%) mean ICC, range 0.05 ( ) 0.04 ( ) 0.09 ( ) 0.04 ( ) Statistical test for Primary Outcome 61 (93.9%) 14 (87.5%) 17 (94.4%) 30 (96.8%) Statistical test accounts for clustering 49 (75.4%) 14 (87.5%) 14 (77.8%) 21 (66.7%) Statistical test adjusts for baseline characteristics 36 (55.4%) 6 (37.5%) 12 (66.7%) 18 (58.1%) Treatment effect present 20 (30.8%) 5 (31.25%) 5 (27.8%) 15 (48.4%)
14 Heterogeneity Analysis in CRTs Subgroup Analyses for Primary Outcomes All Cancer Cardiovascular Pulmonary N =65 N = 16 N = 18 N = 31 Any Subgroup Analysis Performed 14 (21.5%) 2 (16.4%) 9 (50%) 3 (9.7%) Demographic Subgroup Analysis Age Sex Race/Ethnicity Socioeconomic Status Power analysis for Subgroup 1 (1.5%) 0 (0%) 0 (0%) 1 (3.2%) Statistical Test Interaction Testing Other Not Reported HTE found for any subgroup, n (%) HTE found for demographic subgroup, n (%)
15 Quality Assessment of CRT Design 4, 5 Quality Assessment All Cancer Cardiovascular Pulmonary N =65 N = 16 N = 18 N = 31 Justification for cluster design, n (%) 23 (35.4%) 8 (50%) 4 (22.2%) 11 (35.5%) Uses at least 4 clusters per treatment group 58 (89.2%) 13 (81.25%) 16 (88.9%) 29 (93.5%) Allows for clustering in sample size 39 (60%) 10 (62.5%) 12 (66.7%) 17 (54.8%) Uses matching, stratification, or minimization 34 (52.3%) 6 (37.5%) 11 (61.1%) 17 (54.8%) Allows of clusterning in analysis 49 (75.4%) 14 (87.5%) 14 (77.8%) 21 (66.7%) 4. Toklahi Sat al. Occupation, Participation and Health 2016, Vol. 36(1) Eldridge S et al. Clinical Trials, 1(1), doi: / cn006rr
16 Consolidated Standards of Reporting Trial (CONSORT) Guidelines for CRTs 6 Reporting Quality All Cancer Cardiovascular Pulmonary N =65 N = 16 N = 18 N = 31 Cluster RCT in title 36 (55.4%) 11 (68.75%) 8 (44.4%) 17 (54.8%) ICC estimate included 39 (60%) 10 (62.5%) 10 (55.6%) 19 (61.3%) Lists number of clusters randomized 61 (93.8%) 15 (93.75%) 17 (94.4%) 29 (93.5%) Describes baseline comparison of clusters 21 (32.3%) 5 (31.25%) 5 (27.8%) 11 (35.5%) Describes baseline comparison of individuals 62 (95.4%) 16 (100%) 18 (100%) 28 (90.3%) Average cluster size listed 23 (35.4%) 6 (37.5%) 6 (33.3%) 11 (35.5%) Explains whether analysis conducted at the cluster or individual level 38 (58.5) 10 (62.5%) 8 (44.4%) 20 (64.5%) Reports on loss to follow up of clusters 56 (86.2%) 13 (81.25%) 17 (94.4%) 26 (83.9%) Reports on loss to follow up individuals 60 (92.3%) 15 (93.75%) 17 (94.4%) 28 (90.3%) 100% Reporting Quality 7 (10.8%) 2 (12.5%) 1 (5.5%) 4 (12.9%) 6. Cameron, M et al. BMJ 2012;345:e5661 doi: /bmj.e5661
17 Systematic Review: Conclusions Demographic reporting were high for age and sex in CRTs, but less common for race and ethnicity (18.4%). NIH categories rarely listed when race reported. Most trials used matching or stratification for 1-2 cluster variables, but rare to ensure balance by demographics or individual covariates (1 study matched on age). Baseline adjustment in statistical models is common. Most adjust for age and over half adjust for sex. It is rare for race and ethnicity to to be included. HTE analyses in general are very uncommon HTE for race and ethnicity did not occur in our sample
18 Should We Care About Demographic Subgroup Imbalance? Over past 12 months, team of statisticians in biostatistics core: Derived theoretical expressions for treatment effect in CRTs Continuous and binary outcomes Imbalance and HTE Validated assumptions with computer simulation models Examined in real clinical trial stimulations Will focus on results HF-ACTION trial data assessing a continuous outcome
19 HF-ACTION Trial Multicenter, individually randomized controlled trial of exercise training vs usual care 4 Patients with left ventricular dysfunction 35% NYHA class II-IV symptoms despite optimal therapy for 6 weeks Patients randomized from April Feb 2007 at 82 hospitals in the US, Canada, and France Intervention- 3 months of supervised aerobic exercise program with a goal of 3 sessions per week for 36 sessions, followed by home-based exercise 5 times per week for 40 minutes. Primary end-point of all cause mortality or hospitalization. After adjusting for 4 important variables, all cause mortality or all-cause hospitalization (HR 0.89, 95% CI , P=0.03) Trial found significant difference in secondary outcome of 6 minute walk test Connor et al. JAMA. 2009;301(14): doi: /jama
20 CRT Simulations in HF-ACTION Population restricted to include only black and white patients 2175/2331 patients (93.3%) of HF-ACTION Recreated cluster randomized trial by assigning one intervention (treatment or usual care) to all patients in a cluster. Each site served as a cluster 1000 CRTs created by randomly assigning intervention to cluster sites We examined the degree of imbalance and bias created in recreated CRTs. For this analysis, we focus on the continuous outcome of 6- minute walking distance measured at 3 months.
21 Baseline Characteristics in HF-ACTION: Restricted to Blacks and Whites Selected Baseline Exercise Training Usual Care Total Characteristics (N=1075) (N=1100) (N=2175) p value Age at randomization, mean (SD) 0.83 Mean (SD) 59.4 (12.4) 59.1 (13.0) 59.3 (12.7) 0.18 Male Sex 70.3% 72.9% 71.6% Race 0.54 Black or African American 35.1% 33.8% 34.4% White 698 (64.9%) 728 (66.2%) 1426 (65.6%) Distance walked at baseline (m) (102.8) (106.6) (104.7) 0.71 Mean (SD)
22 Results of Walking Distance at 3 Months Using Linear Regression in HF- ACTION RCT Covariate Estimate (meters) 95% CI P-value Exercise Training 23.6 ( ) <0.001 Black Race (-47.7, -17.1) <0.001 Treatment * Race Interaction (-31.2, 11.0) 0.349
23 Racial Variation Among 82 HF-ACTION Sites
24 Imbalance Among Recreated CRT Using HF-ACTION Data Among the 1000 simulated CRTs, the mean ICC is 0.14, with min 0.07 and max 0.21
25 Bias Estimation in CRTs with Continuous Outcomes y ax qt b x t ij ij ij ij ij ij Several effects, but primary interest is to estimate treatment effect (q) accounting for others. Treatment effect heterogeneity (b) is uncommon Effect of covariates (a), e.g. race common Inadequate adjustment for covariates can lead to bias in treatment effect estimate. Bias is proportional to degree of covariate imbalance. Bias U = E( ˆ q ) U -q =a ( X t - X ) c + b ( X t - X ) c
26 Impact of Imbalance of Cluster Race on Bias in 6 Minute Walk Test at 3 Months
27 The Impact of Imbalance of Race on Bias in Treatment Effect: Adjustment Models
28 Summary of Bias in Treatment Effect Using Different Model Adjustment Scenarios Model Adjustment 0% Imbalance 7% Imbalance 14% Imbalance 20% Imbalance Crude Adj. for race Adj. for race and other covariates Pre-post difference in baseline walking distance Conclusion: Bias remains irrespective of adjustment method.
29 Relationship Between Imbalance and Cluster Size
30 Conclusions Imbalance of demographic subgroups may introduce significant bias in treatment effect. If bias greater than treatment effect, can nullify results or reverse treatment effect. If HTE analyses by demographic subgroups are expected, imbalance issues may need to be addressed. Demographics should be consistently collected and reported. Strategies to ensure balanced design may be needed if demographic HTE analyses are to be expected for relevant CRTs.
31 Acknowledgements Systematic Review Gillian Sanders, PhD Remy Coeytaux, MD, PhD Isaretta Riley, MD MPH Larry Jackson, MD MPH Hussein Al-Khalidi, PhD Amanda McBroom Brooks, PhD Kathryn Lallinger Jennifer Gierisch, PhD Simulation Modeling Kingshuk Roy Choudhury, PhD Siyun Yang, MS HF-ACTION investigators- data access Mentor Adrian Hernandez, MD, MHS Grant Management Jill George Tammy Reece
32 Disclosure Research supported by Common Fund Research Supplements To Promote Diversity In Health Related Research under Award Number 3U54AT S1 and the Health Care Systems Research Collaboratory Coordinating Center under Award Number 4U54AT the National Center for Complementary and Integrative Health, a center of the National Institutes of Health. The views presented here are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.
Race and Ethnicity Reporting in Clinical Research and Its Role In Pragmatic Clinical Trials February 28, 2014
Race and Ethnicity Reporting in Clinical Research and Its Role In Pragmatic Clinical Trials February 28, 2014 Monique Anderson, MD Medical Instructor Duke Clinical Research Institute Duke University Medical
More informationRARE-Bestpractices Conference
RARE-Bestpractices Conference 24 November 2016, Istituto Superiore di Sanità, Rome, Italy Avoiding waste in production, design and conduct of studies and reporting evidence on rare diseases Philippe Ravaud
More informationThe influence of CONSORT on the quality of reports of RCTs: An updated review. Thanks to MRC (UK), and CIHR (Canada) for funding support
The influence of CONSORT on the quality of reports of RCTs: An updated review Thanks to MRC (UK), and CIHR (Canada) for funding support Background In 1996 in response to concerns about the quality of reporting
More informationNIH NEW CLINICAL TRIAL REQUIREMENTS AND FORMS-E
NIH NEW CLINICAL TRIAL REQUIREMENTS AND FORMS-E HOW DOES THE NIH DEFINE CLINICAL TRIAL AND HOW DO I KNOW IF MY STUDY IS ONE? 01-18-18 A clinical trial is defined by the NIH as a research study in which
More informationClinically Important Outcomes in ICU research
Clinically Important Outcomes in ICU research Michaël Chassé, MD, PhD, FRCPC Intensivist, Centre Hospitalier de l Université de Montréal Clinical Assistant Professor, Department of Medicine, University
More informationStrategies for Ensuring Diversity, Inclusion, and Meaningful Participation in Clinical Trials: A Workshop
Strategies for Ensuring Diversity, Inclusion, and Meaningful Participation in Clinical Trials: A Workshop Jonca Bull, MD Director, FDA Office of Minority Health The Institute of Medicine, Roundtable on
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationCardiovascular Disease Prevention and Control: Mobile Health (mhealth) Interventions for Treatment Adherence among Newly Diagnosed Patients
Cardiovascular Disease Prevention and Control: Mobile Health (mhealth) Interventions for Treatment Adherence among Newly Diagnosed Patients Community Preventive Services Task Force Finding and Rationale
More informationconfirmatory clinical trials - The PMDA Perspective -
EMA workshop on the investigation of subgroups in confirmatory clinical trials The investigation of subgroups in confirmatory clinical trials - The PMDA Perspective - Yuki Ando Senior Scientist for Biostatistics
More informationUsing Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs
Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs David Manner, Brenda Crowe and Linda Shurzinske BASS XVI November 9-13, 2009 Acknowledgements
More informationClinical Policy Title: Cardiac rehabilitation
Clinical Policy Title: Cardiac rehabilitation Clinical Policy Number: 04.02.02 Effective Date: September 1, 2013 Initial Review Date: February 19, 2013 Most Recent Review Date: February 6, 2018 Next Review
More informationRehabilitation for Cardiovascular Disease: Updates and Opportunities. Jonathan R. Murrow, MD Associate Professor of Medicine (Cardiology)
Rehabilitation for Cardiovascular Disease: Updates and Opportunities Jonathan R. Murrow, MD Associate Professor of Medicine (Cardiology) Disclosures Grants: American Heart Association Grant-in-Aid Novartis
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Drug-eluting balloon angioplasty versus non-stenting balloon angioplasty for peripheral arterial disease of the lower limbs [Cochrane Protocol]
More informationCardiac Rehabilitation for Heart Failure Patients. Jia Shen MD, MPH Assistant Professor of Medicine UC San Diego Health System
Cardiac Rehabilitation for Heart Failure Patients Jia Shen MD, MPH Assistant Professor of Medicine UC San Diego Health System Disclosures There are no conflict of interests related to this presentation.
More informationBIOSTATISTICAL METHODS
BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH PROPENSITY SCORE Confounding Definition: A situation in which the effect or association between an exposure (a predictor or risk factor) and
More informationSCD-HeFT: The Sudden Cardiac Death in Heart Failure Trial
SCD-HeFT: The Sudden Cardiac Death in Heart Failure Trial Gust H. Bardy Seattle Institute for Cardiac Research Seattle, Washington Disclosures Research grants, speaking fees Medtronic Research grants Wyeth
More informationDesigning Multi- center Cluster Randomized Trials: An Introductory Toolkit
Designing Multi- center Cluster Randomized Trials: An Introductory Toolkit Original authors March 2008 Manel Pladevall, MD, Center for Health Services Research, Henry Ford Health System Janine Simpkins,
More informationGuidance for Industry
Reprinted from FDA s website by Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R1) U.S. Department
More informationDo Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus
Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus C. Noel Bairey Merz MD, FACC, FAHA Professor and Women s Guild Endowed Chair Director, Barbra Streisand Women
More informationHeart failure. Complex clinical syndrome. Estimated prevalence of ~2.4% (NHANES)
Heart failure Complex clinical syndrome caused by any structural or functional impairment of ventricular filling or ejection of blood Estimated prevalence of ~2.4% (NHANES) Etiology Generally divided into
More informationRCTs: what s the problem?
An approach for using observational data to enhance the external validity of RCTs Richard Grieve richard.grieve@lshtm.ac.uk RCTs: what s the problem? Heavy investment in RCTs Decision-makers want effectiveness
More informationDownloaded from:
Arnup, SJ; Forbes, AB; Kahan, BC; Morgan, KE; McKenzie, JE (2016) The quality of reporting in cluster randomised crossover trials: proposal for reporting items and an assessment of reporting quality. Trials,
More informationReporting and dealing with missing quality of life data in RCTs: has the picture changed in the last decade?
Qual Life Res (2016) 25:2977 2983 DOI 10.1007/s11136-016-1411-6 REVIEW Reporting and dealing with missing quality of life data in RCTs: has the picture changed in the last decade? S. Fielding 1 A. Ogbuagu
More informationPubH 7405: REGRESSION ANALYSIS. Propensity Score
PubH 7405: REGRESSION ANALYSIS Propensity Score INTRODUCTION: There is a growing interest in using observational (or nonrandomized) studies to estimate the effects of treatments on outcomes. In observational
More informationSupplement DS1 Search strategy. EMBASE Search Strategy
British Journal of Psychiatry doi: 10.1192/bjp.bp.111.106666 Vitamin D deficiency and depression in adults: systematic review and meta-analysis Rebecca E. S. Anglin, Zainab Samaan, Stephen D. Walter and
More informationClinicalTrials.gov "Basic Results" Data Element Definitions (DRAFT)
ClinicalTrials.gov "Basic Results" Data Element Definitions (DRAFT) January 9, 2009 * Required by ClinicalTrials.gov [*] Conditionally required by ClinicalTrials.gov (FDAAA) May be required to comply with
More informationAppendix Document A1: Search strategy for Medline (1960 November 2015)
Appendices: Appendix Document A1: Search strategy for Medline (1960 November 2015) Appendix Table A1: Detailed Risk of Bias Table Appendix Figure A1: Funnel plot Appendix Figure A2: Sensitivity analysis
More informationMortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials
Mortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials Christopher M. O Connor, MD Professor of Medicine Director, Duke Heart Center Acting Chief, Division of Cardiology
More informationA Very Early Rehabilitation Trial (AVERT): What we know, what we think and what s to come
A Very Early Rehabilitation Trial (AVERT): What we know, what we think and what s to come The AVERT Trial Collaboration group Joshua Kwant, Blinded Assessor 17 th May 2016 NIMAST Nothing to disclose Disclosure
More informationMulti-institutional Evaluation of Adherence to Comprehensive Postoperative Venous Thromboembolism Chemoprophylaxis
Multi-institutional Evaluation of Adherence to Comprehensive Postoperative Venous Thromboembolism Chemoprophylaxis D. Brock Hewitt MD MPH, Eddie Blay Jr MD, Lindsey J Kreutzer MPH, Thomas E Kmiecik PhD,
More information6/20/2012. Co-authors. Background. Sociodemographic Predictors of Non-Receipt of Guidelines-Concordant Chemotherapy. Age 70 Years
Sociodemographic Predictors of Non-Receipt of Guidelines-Concordant Chemotherapy - among Locoregional Breast Cancer Patients Under Age 70 Years Xiao-Cheng Wu, MD, MPH 2012 NAACCR Annual Conference June
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Percutaneous access for endovascular aortic aneurysm repair: a systematic review and meta-analysis Shahin Hajibandeh, Shahab Hajibandeh,
More informationEpidemiology of Asthma. In Wayne County, Michigan
Epidemiology of Asthma In Wayne County, Michigan Elizabeth Wasilevich, MPH Asthma Epidemiologist Bureau of Epidemiology Michigan Department of Community Health 517.335.8164 Publication Date: August 2005
More informationThe QUOROM Statement: revised recommendations for improving the quality of reports of systematic reviews
The QUOROM Statement: revised recommendations for improving the quality of reports of systematic reviews David Moher 1, Alessandro Liberati 2, Douglas G Altman 3, Jennifer Tetzlaff 1 for the QUOROM Group
More informationExperimental Design. Terminology. Chusak Okascharoen, MD, PhD September 19 th, Experimental study Clinical trial Randomized controlled trial
Experimental Design Chusak Okascharoen, MD, PhD September 19 th, 2016 Terminology Experimental study Clinical trial Randomized controlled trial 1 PHASES OF CLINICAL TRIALS Phase I: First-time-in-man studies
More informationConnecting the Dots: Cluster Randomized Trial. Behavioral Economics and a. Adrian F. Hernandez, MHS
Connecting the Dots: Behavioral Economics and a Cluster Randomized Trial Adrian F. Hernandez, MHS Disclosures Research grant to the Duke Clinical Research Institute from: Novartis (Independent Investigator
More informationClinicalTrials.gov a programmer s perspective
PhUSE 2009, Basel ClinicalTrials.gov a programmer s perspective Ralf Minkenberg Boehringer Ingelheim Pharma GmbH & Co. KG PhUSE 2009, Basel 1 Agenda ClinicalTrials.gov Basic Results disclosure Initial
More informationWhat can we learn from the AVERT trial (so far)?
South West Stroke Network Event, 29 th April, 2015 What can we learn from the AVERT trial (so far)? Peter Langhorne, Professor of stroke care, Glasgow University Disclosure PL was AVERT investigator and
More informationFDA SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED) CLINICAL SECTION CHECKLIST OFFICE OF DEVICE EVALUATION
FDA SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED) CLINICAL SECTION CHECKLIST OFFICE OF DEVICE EVALUATION Note to FDA PMA Reviewers: The Summary of Safety and Effectiveness (SSED) is a document mandated
More informationVarenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks?
Varenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks? Sonal Singh M.D., M.P.H, Johns Hopkins University Presented by: Sonal Singh, MD MPH September 19, 2012 1 CONFLICTS
More informationCardiovascular Disease and Commercial Motor Vehicle Driver Safety. Physical Qualifications Division April 10, 2007
Federal Motor Carrier Safety Administration Executive Summary Cardiovascular Disease and Commercial Motor Vehicle Driver Safety Presented to Physical Qualifications Division April 10, 2007 Prepared by:
More informationAppendix Identification of Study Cohorts
Appendix Identification of Study Cohorts Because the models were run with the 2010 SAS Packs from Centers for Medicare and Medicaid Services (CMS)/Yale, the eligibility criteria described in "2010 Measures
More informationSchool of Public Health Academic Years Course Rotation
Academic Years 2018 2020 Course Dept Prefix Catalog. Course Title Credits Grading Fall Spring 6W1 6W2 12W HPBS PHM 1110L Health Promotion and Behavioral Sciences in Public Health 3 GRD Every Every Every
More informationAppendices. Appendix A Search terms
Appendices Appendix A Search terms Database Search terms Medline 1. Ipilimumab; 2. MDX-010; 3. MDX-101; 4. Yervoy; 5. BMS-734016; 6. Nivolumab; 7. ONO-4538; 8. BMS-936558; 9. MDX-1106; 10. Opdivo; 11.
More informationRemote management of heart failure using implanted devices and formalized follow-up procedures (REM-HF)
Remote management of heart failure using implanted devices and formalized follow-up procedures (REM-HF) Martin R Cowie Professor of Cardiology, Imperial College London (Royal Brompton Hospital) London,
More informationResults. NeuRA Forensic settings April 2016
Introduction Prevalence quantifies the proportion of individuals in a population who have a disease during a specific time period. Many studies have reported a high prevalence of various health problems,
More informationUSE OF ACCELEROMETER DATA TO EVALUATE PHYSICAL ACTIVITY AS A SURROGATE ENDPOINT IN HEART FAILURE CLINICAL TRIALS. Tracy Bergemann PhD
USE OF ACCELEROMETER DATA TO EVALUATE PHYSICAL ACTIVITY AS A SURROGATE ENDPOINT IN HEART FAILURE CLINICAL TRIALS Tracy Bergemann PhD Senior Principal Statistician ASA Biopharmaceutical Section Regulatory-Industry
More informationClinical Study Design: From Pilot to Randomized Controlled Trials
Clinical Study Design: From Pilot to Randomized Controlled Trials Thomas C. Hulsey, MSPH, Sc.D. Professor and Chair, Department of Epidemiology Director, Clinical Research Education, CTSI What is a clinical
More informationCLASSIFICATION TREE ANALYSIS:
CLASSIFICATION TREE ANALYSIS: A USEFUL STATISTICAL TOOL FOR PROGRAM EVALUATORS Meredith L. Philyaw, MS Jennifer Lyons, MSW(c) Why This Session? Stand up if you... Consider yourself to be a data analyst,
More informationMDCH IRB REVIEW APPLICATION Authority: Code of Federal Regulations Title 45 Part 46
The Michigan Department of Community Health Institutional Review Board for the Protection of Human Research Subjects Capitol View Building, 7 th Floor, 201 Townsend Street, Lansing, MI 48913 Phone: 517/241-1928
More informationHCHS/SOL Submission Instructions for Manuscripts or Publications
HCHS/SOL Submission Instructions for Manuscripts or Publications What is this? This is an example of an ideal submission of manuscripts or publications on the HCHS/SOL website. This example describes the
More informationResults. NeuRA Treatments for internalised stigma December 2017
Introduction Internalised stigma occurs within an individual, such that a person s attitude may reinforce a negative self-perception of mental disorders, resulting in reduced sense of selfworth, anticipation
More informationUsing Patient Navigation to Impact Trust in the Health Care System
Using Patient Navigation to Impact Trust in the Health Care System ARANTZA RODRIGUEZ PUERTOS MENTOR: CARMEN E. GUERRA, M.D., M.S.C.E., F.A.C.P. Introduction Data and Methods Outline Key Findings and Discussion
More informationHF and CRT: CRT-P versus CRT-D
HF and CRT: CRT-P versus CRT-D Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief, Cardiology Section Philadelphia VA Medical Center Philadelphia, PA
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationStatistical Analysis Plans
Statistical Analysis Plans PROFESSOR CARROL GAMBLE UNIVERSITY OF LIVERPOOL Clinical Trials Lots of different types of clinical trials Various interventions Pharmaceutical/drugs regulated Regulated environment
More informationStudy protocol v. 1.0 Systematic review of the Sequential Organ Failure Assessment score as a surrogate endpoint in randomized controlled trials
Study protocol v. 1.0 Systematic review of the Sequential Organ Failure Assessment score as a surrogate endpoint in randomized controlled trials Harm Jan de Grooth, Jean Jacques Parienti, [to be determined],
More informationBending the Cost Curve Through Comparative Effectiveness Research. ASCO 2012 Sean Tunis MD, MSc June 2, 2012
Bending the Cost Curve Through Comparative Effectiveness Research ASCO 2012 Sean Tunis MD, MSc June 2, 2012 Evidence Summary: Radiation Therapy for Comparisons Clinically Localized Prostate Cancer Disease
More informationIncorporating External Data into Existing Longitudinal Studies
Incorporating External Data into Existing Longitudinal Studies Public Workshop: Addressing Inadequate Information on Important Health Factors in Pharmacoepidemiology Studies Relying on Healthcare Databases
More informationQuality and Reporting Characteristics of Network Meta-analyses: A Scoping Review
Quality and Reporting Characteristics of Network Meta-analyses: A Scoping Review Andrea C. Tricco MSc, PhD Scientist, Li Ka Shing Knowledge Institute of St. Michael s Hospital Assistant Professor, Dalla
More informationIdentifying Geographic & Socioeconomic Disparities in Access to Care for Pediatric Cancer Patients in Texas
Identifying Geographic & Socioeconomic Disparities in Access to Care for Pediatric Cancer Patients in Texas Mary T. Austin, MD, MPH Assistant Professor, Pediatric Surgery University of Texas Health Science
More informationThe Role of Cardiac Rehabilitation. The Role of Cardiac Rehabilitation. in Heart Failure. in Heart Failure. History of Cardiac Rehab.
The Role of Cardiac Rehabilitation The Role of Cardiac Rehabilitation in Heart Failure in Heart Failure Kate Traynor RN MS FAACVPR Financial Disclosures No relevant financial relationship exists. History
More informationAccelerating Patient-Centered Outcomes Research and Methodological Research
Accelerating Patient-Centered Outcomes Research and Methodological Research Jason Gerson, PhD CER Methods JSM 2016 July 31, 2016 In This Session PCORI Overview Methods Program Overview Methods Program
More informationSPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM
SPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM Rio De Janeiro 2016 Sport and Exercise Cardiology Symposium SBC/SOCERJ ACC Sharlene M. Day, MD Associate Professor, Cardiovascular Medicine Director,
More informationCONSORT: missing missing data guidelines, the effects on HTA monograph reporting Yvonne Sylvestre
CONSORT: missing missing data guidelines, the effects on HTA monograph reporting Yvonne Sylvestre Clinical Trials Methodology Conference, 5 th of October 2011 NWORTH North Wales Organisation for Randomised
More informationDesign and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009
Design and Analysis of a Cancer Prevention Trial: Plans and Results Matthew Somerville 09 November 2009 Overview Objective: Review the planned analyses for a large prostate cancer prevention study and
More informationOther potential bias. Isabelle Boutron French Cochrane Centre Bias Method Group University Paris Descartes
Other potential bias Isabelle Boutron French Cochrane Centre Bias Method Group University Paris Descartes 1 Outlines RoB tool for specific design Cross over trial Cluster randomized controlled trials Mono
More informationDisparities in Vison Loss and Eye Health
Disparities in Vison Loss and Eye Health Xinzhi Zhang, MD, PhD, FACE, FRSM National Institute on Minority Health and Health Disparities National Institutes of Health Disclaimer The findings and conclusions
More informationHypertension JNC 8 (2014)
Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology
More informationMarket Access CTR Summary
Market Access CTR Summary Study No.: BEL114246 Title: Efficacy of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: A Pooled Analysis of the HGS1006-C1056 (BLISS-52)
More informationIntegrative Medicine Group Visits: Who Does Well in the Group Visits and Who Attends the Group Visits?
+ Integrative Medicine Group Visits: Who Does Well in the Group Visits and Who Attends the Group Visits? Integrative Medicine for the Underserved Conference, 2018 Paula Gardiner MD MPH Man Luo MPH Salvatore
More informationHealth Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial
Health Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial Suzanne V. Arnold, MD, MHA Saint Luke s Mid America
More informationAsthma Pharmacotherapy Adherence Interventions for Adult African-Americans: A Systematic Review. Isaretta L. Riley, MD
Asthma Pharmacotherapy Adherence Interventions for Adult African-Americans: A Systematic Review By Isaretta L. Riley, MD A Master s Paper submitted to the faculty of the University of North Carolina at
More informationAssociation between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis
Association between the CYP11B2 gene 344T>C polymorphism and coronary artery disease: a meta-analysis Y. Liu, H.L. Liu, W. Han, S.J. Yu and J. Zhang Department of Cardiology, The General Hospital of the
More informationClinical Outcomes of Women with Peripartum Cardiomyopathy With and Without Preeclampsia: a Population-based Study
Clinical Outcomes of Women with Peripartum Cardiomyopathy With and Without Preeclampsia: a Population-based Study Isabelle Malhamé, MSc Candidate in Epidemiology, McGill University Obstetric Medicine Fellow,
More informationEpidemiology of Asthma. In the Western Michigan Counties of. Kent, Montcalm, Muskegon, Newaygo, and Ottawa
Epidemiology of Asthma In the Western Michigan Counties of Kent, Montcalm, Muskegon, Newaygo, and Ottawa Elizabeth Wasilevich, MPH Asthma Epidemiologist Bureau of Epidemiology Michigan Department of Community
More informationCALIFORNIA STATE UNIVERSITY STANISLAUS DEPARTMENT OF SOCIOLOGY ASSESSMENT MODEL
CALIFORNIA STATE UNIVERSITY STANISLAUS DEPARTMENT OF SOCIOLOGY ASSESSMENT MODEL Introduction The purpose of assessment in education is to create a model that can quantify the degree of program success
More informationRedefining Cardiac Eligibility Thresholds in Oncology Trials. Role of Cardiovascular Core Labs
Redefining Cardiac Eligibility Thresholds in Oncology Trials. Role of Cardiovascular Core Labs Ana Barac, MD, PhD, FACC Associate Professor of Medicine, Georgetown University MedStar Heart and Vascular
More informationSUPPLEMENTARY DATA. Supplementary Figure S1. Search terms*
Supplementary Figure S1. Search terms* *mh = exploded MeSH: Medical subject heading (Medline medical index term); tw = text word; pt = publication type; the asterisk (*) stands for any character(s) #1:
More informationRacial and Socioeconomic Disparities in Appendicitis
Racial and Socioeconomic Disparities in Appendicitis Steven L. Lee, MD Chief of Pediatric Surgery, Harbor-UCLA Associate Clinical Professor of Surgery and Pediatrics David Geffen School of Medicine at
More informationThe Use of Clinical Trial Data in Combination with External Data Sources to Examine Novel Cancer Research Questions: A Modified Big Data Approach
The Use of Clinical Trial Data in Combination with External Data Sources to Examine Novel Cancer Research Questions: A Modified Big Data Approach Joseph Unger, Ph.D. Assistant Member, Public Health Sciences
More informationCochrane Pregnancy and Childbirth Group Methodological Guidelines
Cochrane Pregnancy and Childbirth Group Methodological Guidelines [Prepared by Simon Gates: July 2009, updated July 2012] These guidelines are intended to aid quality and consistency across the reviews
More informationThe Role of ICD Therapy in Cardiac Resynchronization
The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine
More informationFang Hua 1,2*, Tanya Walsh 2, Anne-Marie Glenny 2 and Helen Worthington 2*
Hua et al. BMC Medical Research Methodology (2018) 18:6 DOI 10.1186/s12874-017-0469-3 RESEARCH ARTICLE Open Access Structure formats of randomised controlled trial abstracts: a cross-sectional analysis
More informationCochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library)
A systematic review of smoking cessation and relapse prevention interventions in parents of babies admitted to a neonatal unit (after delivery) Divya Nelson, Sarah Gentry, Caitlin Notley, Henry White,
More informationAnimal-assisted therapy
Introduction Animal-assisted interventions use trained animals to help improve physical, mental and social functions in people with schizophrenia. It is a goal-directed intervention in which an animal
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationTitle: Authors: Background: Research Design: Analysis:
Title: The Effects of a Purpose for Learning Mindset Intervention on Low-Income High School Students Academic Success Authors: Jill Gandhi, Tyler W. Watts, C. Cybele Raver Background: Many mindset interventions
More informationGuidance for Industry Migraine: Developing Drugs for Acute Treatment
Guidance for Industry Migraine: Developing Drugs for Acute Treatment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
More informationTraumatic brain injury
Introduction It is well established that traumatic brain injury increases the risk for a wide range of neuropsychiatric disturbances, however there is little consensus on whether it is a risk factor for
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationUW School of Public Health Lecture. Clinical Trials: Discerning Hype from Substance
UW School of Public Health Lecture Clinical Trials: Discerning Hype from Substance February 26, 2009 Thomas R. Fleming, Ph.D. Professor of Biostatistics University of Washington tfleming@u.washington.edu
More informationIntegrating Effectiveness and Safety Outcomes in the Assessment of Treatments
Integrating Effectiveness and Safety Outcomes in the Assessment of Treatments Jessica M. Franklin Instructor in Medicine Division of Pharmacoepidemiology & Pharmacoeconomics Brigham and Women s Hospital
More informationCombination therapy compared to monotherapy for moderate to severe Alzheimer's Disease. Summary
Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease Summary Mai 17 th 2017 Background Alzheimer s disease is a serious neurocognitive disorder which is characterized
More informationThe Impact of Cellphone Sample Representation on Variance Estimates in a Dual-Frame Telephone Survey
The Impact of Cellphone Sample Representation on Variance Estimates in a Dual-Frame Telephone Survey A. Elizabeth Ormson 1, Kennon R. Copeland 1, B. Stephen J. Blumberg 2, and N. Ganesh 1 1 NORC at the
More informationCONSORT 2010 checklist of information to include when reporting a randomised trial*
CONSORT 2010 checklist of information to include when reporting a randomised trial* Section/Topic Title and abstract Introduction Background and objectives Item No Checklist item 1a Identification as a
More informationHealth Disparities Research. Kyu Rhee, MD, MPP, FAAP, FACP Chief Public Health Officer Health Resources and Services Administration
Health Disparities Research Kyu Rhee, MD, MPP, FAAP, FACP Chief Public Health Officer Health Resources and Services Administration Outline on Health Disparities Research What is a health disparity? (DETECT)
More informationBisphosphonates and other bone agents for breast cancer(review)
Cochrane Database of Systematic Reviews Bisphosphonates and other bone agents for breast cancer (Review) O Carrigan B, Wong MHF, Willson ML, Stockler MR, Pavlakis N, Goodwin A O Carrigan B, Wong MHF, Willson
More informationPediatric Anti-bacterial and Anti-fungal Trials from 2007 to 2015: A Systematic Review of ClinicalTrials.gov
Pediatric Anti-bacterial and Anti-fungal Trials from 2007 to 2015: A Systematic Review of ClinicalTrials.gov Joshua Thaden, MD, PhD Fellow, Infectious Diseases Duke University April 5, 2016 Objectives
More information